title: Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy.
abstract: Metastatic or unresectable disease is identified in approximately 20% of patients presenting with invasive urothelial cancer. In addition, up to 50% of patients will develop metastases following radical cystectomy for clinically localized disease. Multiagent cisplatin-based chemotherapy is considered standard first-line treatment for these patients. Although urothelial cancer is considered a chemosensitive tumour, metastatic disease is associated with poor prognosis and short-term survival. Here, we review the role of a multidisciplinary approach to treating patients with metastatic urothelial cancer.
authors.affiliation: The University of Texas MD Anderson Cancer Center, Department of Urologic Oncology;
authors.forename: Robert S
authors.initials: RS
authors.lastname: Svatek
authors.forename: Arlene
authors.initials: A
authors.lastname: Siefker-Radtke
authors.forename: Colin P
authors.initials: CP
authors.lastname: Dinney